The Korean Journal of Urological Oncology 2013;11(1):6-10.
Published online April 30, 2013.
전이 거세저항성 전립선암의 예후인자
김재헌, 양원재
순천향대학교 의과대학 비뇨기과학교실
Risk Factors for Metastatic Castrate-Resistant Prostate Cancer
Jae Heon Kim , Won Jae Yang
Department of Urology, Soonchunhyang University College of Medicine, Seoul, Korea
Correspondence:  Won Jae Yang
Prostate cancer remains the most common type of cancer in men and the development of castrate-resistant disease seems inevitable. Metastatic castrate-resistant prostate cancer(mCRPC) is known to have a poor prognosis although some new chemotherapy, immunotherapy, and target therapy showed improvement in overall survival, which together drive a new treatment strategy for better prognosis. For risk factors of mCRPC, it could be divided by the period of 2004, in which Docetaxel treatment was established as standard method for mCRPC. The aim of this study is to describe risk factors for the prognosis of mCRPC. (Korean J Urol Oncol 2013;11:6-10)
Key Words: Castrate-resistant prostate cancer, Prognosis, Chemotherapy, Immunotherapy

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email:                

Copyright © The Korean Urological Oncology Society.

Developed in M2PI